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Intravenous Abciximab
Bolus Administration
We thank Dr. De Rosa and colleagues for the interest in our work
(1,2). We agree that the AIDA STEMI (Abciximab i.v. Versus i.c.
in ST-elevation Myocardial Infarction) trial might have been un-
derpowered to detect small differences in clinical event rates be-
tween the treatment arms (if there are any). The absolute difference
in the incidence of the primary endpoint between groups was only
0.6%. Thus, if one were to plan a new trial with a similar design
considering this numerical difference as the true population value,
the required total sample size would exceed 70,000 patients to reach
statistical signiﬁcance. It remains speculative whether particular
(supposedly high-risk) patients might nevertheless beneﬁt from
intracoronary bolus delivery. However, there was no beneﬁt of
intracoronary bolus administration in any of the subgroups studied
with the exception of female patients (which might be a chance
ﬁnding given the lack of a plausible biological explanation). In light
of the meta-regression analysis presented by Dr. De Rosa and
colleagues, which suggested that there is a beneﬁt of intracoronary
abciximab in patients with decreased left ventricular ejection frac-
tion (LVEF), we performed an exploratory subgroup analysis in
AIDA STEMI trial patients with an LVEF <50% and 50% with
respect to the composite endpoint at 1 year. There was no evidence
of a beneﬁcial effect of intracoronary abciximab in patients with
reduced LVEF (LVEF <50%: event rates 14.6% intracoronary vs.
16.0% intravenous; odds ratio: 0.90 [95% conﬁdence interval: 0.58
to 1.39]; LVEF 50%: event rates 5.7% intracoronary vs. 4.5%
intravenous; odds ratio: 1.27 [95% conﬁdence interval: 0.74 to
2.18]; p value for interaction ¼ 0.34). These clinical ﬁndings are
supported by the magnetic resonance substudy of the AIDA
STEMI trial, which found no signiﬁcant differences for established
surrogate markers such as infarct size and microvascular obstruction
between intracoronary and intravenous bolus administration (3).
Further, in the recently published INFUSE-AMI trial including
only high-risk ST-segment elevation myocardial infarction patients
with proximal or mid-left anterior descending artery occlusion, the
magnitude of the absolute infarct size reduction with intracoronary
bolus abciximab (without subsequent low-dose infusion) versus
no abciximab was only modest and was not accompanied by other
markers of reperfusion success (4).
In the era of a high percentage of pre-loading with other potent
antiplatelet agents such as prasugrel and ticagrelor, the magnitude
of the short-lived local effect of direct intracoronary abciximab
bolus delivery might simply not be enough to produce clinically
meaningful effects.*Steffen Desch, MD
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We read with interest the paper of Eindhoven et al. (1) under-
scoring the clinical usefulness of N-terminal pro–B-type natriuretic
peptide (NT-proBNP) in adult patients with different congenital
heart diseases (CHDs), even corrected or palliated. Plasma levels of
NT-proBNP differing by diagnosis were correlated with most
relevant echocardiographic morphological and functional indexes,
as well as in a subset of patients undergoing cardiopulmonary stress
testing, with exercise capacity. This work extends actual knowledge
of the utility of both BNP and NT-proBNP as diagnostic tools in
adult patients with CHD (2–8), conﬁrming known age and sex
inﬂuence while specifying a differential role of left and right ven-
tricular involvement with regard to natriuretic peptide (NP) pro-
duction and secretion in each CHD analyzed. Moreover, the work
conﬁrms that the NP level is associated with functional capacity,
even in asymptomatic CHD patients (2–5).
The authors must be congratulated for their successful attempt to
analyze the effect of surgical correction/palliation of NT-proBNP
levels in adults with different CHDs. They add the notion that
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1343NT-proBNP levels, measured during follow-up, does not neces-
sarily correlate with the severity of the initial disease and that
NT-proBNP levels change, in a different way, according to the
underlying disease. This ﬁnding is surprising. In fact, although
a higher NT-proBNP is likely in adults with Fontan circulation and
a systemic right ventricle, it is unexpected the ﬁnding of either a
higher NT-proBNP in adult patients after atrial defect closure or of
normal levels in patients undergoing arterial switch or aortic
coarctation repair, at long-term follow-up (1,4–7).
The ﬁnal lesson is that absolute NP levels must be read in the
context of the speciﬁc CHD and from the perspective of the in-
dividual patient’s outcome. The NT-proBNP plasma level mirrors
the inﬂuence of diverse factors and is an expression not only of
hemodynamic overload on either the right or left heart, but also of
noncardiac confounders, such as age and sex (with the need to
adapt reference values throughout the patient’s life span) (4,5), as
well as others that have not been taken into account in this work
such as renal function and neurohormonal activation (9). There-
fore, the measurement of cardiac endocrine function should be
considered as part of a multimarker approach, including reﬁned
echocardiographic or cardiac magnetic resonance evaluation and
assessment of functional capacity by means of cardiopulmonary
stress testing aimed at the most objective therapeutic decision
making, in particular at the evaluation of timing of surgical redo.*Massimiliano Cantinotti, MD
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We thank Dr. Cantinotti and colleagues for their response to our
paper (1) describing the clinical usefulness of N-terminal pro–B-
type natriuretic peptide (NT-proBNP) in adults with congenital
heart disease (CHD) and showing correlations with echocardio-
graphic and exercise parameters.
As Dr. Cantinotti and colleagues state, the ﬁnding that the
NT-proBNP level was not correlated with the severity of the
initial disease was unexpected. NT-proBNP levels in patients with
surgically corrected atrial septal defects are known to be slightly
elevated (2). However, the remarkably low NT-proBNP levels in
patients after undergoing an arterial switch operation are surprising
and, together with their normal cardiac function and exercise
capacity, all mirror a good clinical condition. These are promising
factors for the long-term outcome of these patients. Because this is
the ﬁrst report of NT-proBNP in adults undergoing an arterial
switch operation and our study population was relatively small,
further research on these patients is clearly warranted.
We agree with Dr. Cantinotti and colleagues that absolute
NT-proBNP levels must be interpreted in the context of the in-
dividual patient characteristics. Noncardiac factors including age,
sex, and renal function are known to inﬂuence NT-proBNP levels
(3); therefore, patients with renal dysfunction were excluded from
our study, and in our statistical analyses, we adjusted for age and
sex. Nevertheless, all adults with CHD have a unique medical
history, with or without cyanosis and varying from no to multiple
surgical interventions, that may have inﬂuenced cardiac loading
conditions and consequent NT-proBNP release. Future research
should focus on the various CHDs in combination with patients’
medical history to improve interpretation of individual B-type
natriuretic peptide (BNP) results.
The production and excretion of BNP and NT-proBNP is a
complex process that is inﬂuenced by mechanical, neurohormonal,
and immunological factors (4), and novel cardiac biomarkers such
as ST2, galectin-3, and GDF-15 (5,6) have been gaining in in-
terest recently. Possibly, in the future, a multimarker approach
together with established diagnostic tools could improve decision
making in the specialist care of this unique patient population.Jannet A. Eindhoven, MD
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